EAGLE PHARMACEUTICALS INC's ticker is EGRX and the CUSIP is 269796108. A total of 178 filers reported holding EAGLE PHARMACEUTICALS INC in Q2 2017. The put-call ratio across all filers is 0.42 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $300,135 | -21.4% | 19,032 | -3.1% | 0.00% | – |
| Q2 2023 | $381,685 | +1047.9% | 19,634 | +1575.3% | 0.00% | – |
| Q1 2023 | $33,250 | +446.9% | 1,172 | +463.5% | 0.00% | – |
| Q4 2022 | $6,080 | -98.2% | 208 | -98.4% | 0.00% | – |
| Q3 2022 | $340,000 | -77.4% | 12,901 | -61.9% | 0.00% | – |
| Q2 2022 | $1,505,000 | +134.8% | 33,880 | +161.6% | 0.00% | – |
| Q1 2022 | $641,000 | +12720.0% | 12,953 | +12853.0% | 0.00% | – |
| Q4 2021 | $5,000 | -16.7% | 100 | -6.5% | 0.00% | – |
| Q3 2021 | $6,000 | -14.3% | 107 | -40.2% | 0.00% | – |
| Q2 2021 | $7,000 | +16.7% | 179 | +19.3% | 0.00% | – |
| Q1 2021 | $6,000 | +20.0% | 150 | +50.0% | 0.00% | – |
| Q4 2020 | $5,000 | +25.0% | 100 | 0.0% | 0.00% | – |
| Q3 2020 | $4,000 | -20.0% | 100 | 0.0% | 0.00% | – |
| Q2 2020 | $5,000 | -99.8% | 100 | -99.8% | 0.00% | – |
| Q1 2020 | $2,226,000 | -23.1% | 48,390 | +0.4% | 0.00% | – |
| Q4 2019 | $2,896,000 | -38.1% | 48,208 | -41.7% | 0.00% | -100.0% |
| Q3 2019 | $4,680,000 | -24.9% | 82,726 | -26.1% | 0.00% | 0.0% |
| Q2 2019 | $6,232,000 | -24.8% | 111,925 | -31.8% | 0.00% | 0.0% |
| Q1 2019 | $8,287,000 | +22.9% | 164,125 | -1.9% | 0.00% | 0.0% |
| Q4 2018 | $6,742,000 | -59.2% | 167,325 | -29.8% | 0.00% | -50.0% |
| Q3 2018 | $16,530,000 | -24.3% | 238,421 | -17.4% | 0.00% | -33.3% |
| Q2 2018 | $21,829,000 | +29.1% | 288,509 | -10.1% | 0.00% | +50.0% |
| Q1 2018 | $16,914,000 | -1.4% | 321,009 | +0.0% | 0.00% | 0.0% |
| Q4 2017 | $17,147,000 | -10.4% | 320,992 | 0.0% | 0.00% | 0.0% |
| Q3 2017 | $19,144,000 | -26.4% | 320,992 | -2.6% | 0.00% | -33.3% |
| Q2 2017 | $25,994,000 | -2.4% | 329,495 | +2.6% | 0.00% | 0.0% |
| Q1 2017 | $26,623,000 | +264.7% | 320,992 | +248.9% | 0.00% | +200.0% |
| Q4 2016 | $7,300,000 | +24.6% | 92,011 | -36.4% | 0.00% | 0.0% |
| Q1 2016 | $5,858,000 | +45.0% | 144,650 | +217.6% | 0.00% | 0.0% |
| Q4 2015 | $4,039,000 | +260.0% | 45,550 | +200.7% | 0.00% | – |
| Q3 2015 | $1,122,000 | – | 15,150 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ProQuest Associates IV LLC | 3,652,284 | $302,920,000 | 91.10% |
| Hudson Executive Capital LP | 1,901,200 | $157,686,000 | 21.62% |
| JW Asset Management, LLC | 525,755 | $43,606,000 | 9.08% |
| Cormorant Asset Management, LP | 200,000 | $16,588,000 | 2.41% |
| Park West Asset Management LLC | 488,128 | $40,485,000 | 2.36% |
| Opaleye Management Inc. | 50,000 | $4,147,000 | 2.06% |
| Ranger Investment Management | 283,954 | $23,551,000 | 1.71% |
| Pier Capital, LLC | 74,732 | $6,198,000 | 1.06% |
| Bellevue Group AG | 67,700 | $5,615,000 | 0.75% |
| Orbimed Advisors | 671,000 | $55,653,000 | 0.63% |